Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to $954000.0.

  • Dianthus Therapeutics' Current Deferred Revenue rose 85400.0% to $954000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $954000.0, marking a year-over-year increase of 85400.0%. This contributed to the annual value of $479000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Current Deferred Revenue is $954000.0, which was up 85400.0% from $479000.0 recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Current Deferred Revenue ranged from a high of $954000.0 in Q3 2025 and a low of $100000.0 during Q4 2022
  • For the 4-year period, Dianthus Therapeutics' Current Deferred Revenue averaged around $321222.2, with its median value being $100000.0 (2022).
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first changed by 0.0% in 2024, then skyrocketed by 85400.0% in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Current Deferred Revenue (Quarter) stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then surged by 379.0% to $479000.0 in 2024, then skyrocketed by 99.16% to $954000.0 in 2025.
  • Its Current Deferred Revenue was $954000.0 in Q3 2025, compared to $479000.0 in Q2 2025 and $479000.0 in Q1 2025.